Icon Pub Ltd Co (NASDAQ:ICLR)

CAPS Rating: 4 out of 5

The Company is a contract research organization, providing clinical research and development services on a global basis to the pharmaceutical, biotechnology and medical device industries.

Results 1 - 20 of 38 : 1 2 Next »

Recs

0
Member Avatar Flygal5 (99.27) Submitted: 9/15/2014 11:22:56 AM : Outperform Start Price: $55.21 ICLR Score: +0.53

contract research for pharma

Recs

0
Member Avatar TMFHelical (98.85) Submitted: 9/4/2014 10:40:00 AM : Outperform Start Price: $15.91 ICLR Score: +189.83

Long term trend in pharma outsourcing. Bought on weakness.

Recs

0
Member Avatar PatientJC (32.09) Submitted: 2/10/2014 2:38:23 PM : Underperform Start Price: $45.37 ICLR Score: -12.05

underwhelming fundamentals

Recs

0
Member Avatar quinnathome (32.10) Submitted: 4/10/2013 3:14:49 PM : Outperform Start Price: $30.90 ICLR Score: +54.81

Well-run international company in an industry that is sure to grow as healthcare costs continue to rise.

Recs

1
Member Avatar CellBlock9 (91.15) Submitted: 1/11/2013 1:34:36 PM : Outperform Start Price: $23.92 ICLR Score: +87.43

S &P 5 star

Recs

0
Member Avatar pennysplants (99.60) Submitted: 11/22/2012 4:42:55 PM : Outperform Start Price: $18.00 ICLR Score: +77.07

Reassess long term position. Strongest going forward in this sector? Cleaning up after 2 year hiatus from CAPS.

Recs

0
Member Avatar TMFRisingStars (< 20) Submitted: 7/29/2011 10:21:20 AM : Outperform Start Price: $22.28 ICLR Score: +96.43

Here's the buy rec:
http://www.fool.com/investing/general/2011/07/27/rising-stars-buy-icon.aspx

Recs

0
Member Avatar RENNOTA (< 20) Submitted: 10/15/2010 12:45:04 PM : Outperform Start Price: $21.19 ICLR Score: +94.02

True to my style, this stock has all the makings of a security whose price understates the value of the underlying business. This company produces some pretty impressive margins, while still maintaining a very healthy balance sheet. The firm also sticks to its core competencies beautifully, indicating a disciplined, intelligent management.
I also like this stock because, in addition to currently looking attractive, it incorporates a larger, macro play. It stands to grow revenue as pharmaceutical companies increasingly outsource their testing operations in an effort to cut costs. I think this stock appears poised to outperform the broad market index.

Recs

0
Member Avatar scoobamang (< 20) Submitted: 11/15/2009 6:37:48 PM : Outperform Start Price: $22.65 ICLR Score: +65.72

Good fundamentals, steady growth in revenue and profit. It seems like they recently made some acquisitions and this is the reason it dropped down from $40, which I think it should return to relatively soon. Very little debt!

Recs

0
Member Avatar cfackler (95.46) Submitted: 10/22/2009 9:59:44 AM : Outperform Start Price: $25.42 ICLR Score: +34.48

I love companies that serve other companies. Regardless of the success or failure of a drug trial, this company makes money.

Recs

0
Member Avatar ftblfntk56 (< 20) Submitted: 6/4/2009 7:44:36 PM : Outperform Start Price: $20.12 ICLR Score: +66.36

I sold this stock today. I bought in at $15 last month and I am taking my 36% profit. I have it written down to get out before July as I feel the stock will have some poorer earnings reports. However, long term this stock is a sure fire winner, just not the next month. I'll re-evaluate it in August.

Recs

0
Member Avatar kevinottofro (98.62) Submitted: 4/25/2009 9:02:42 AM : Outperform Start Price: $15.25 ICLR Score: +131.17

Low relative PE, good star ranking, PEG & 09 PE still below normal - bottom fishing 4/27 picks.

Recs

0
Member Avatar Trimalerus (90.19) Submitted: 4/6/2009 4:10:23 PM : Outperform Start Price: $17.28 ICLR Score: +77.69

A good buy even at $23 according to the high scores on the Scorecard. Near 52 week low. Healthcare industry has high growth potential. Followed another 99% member to this pick.

Recs

0
Member Avatar hondo928 (99.63) Submitted: 3/10/2009 4:19:24 PM : Outperform Start Price: $18.00 ICLR Score: +77.38

They claim to have been hurt by a strong dollar, great news since Comrade Obama loves inflation and a weak dollar.

Recs

0
Member Avatar WakeJKirk (54.70) Submitted: 12/23/2008 9:06:05 PM : Outperform Start Price: $17.66 ICLR Score: +81.22

ICLR is a very solid company that I consider to be on the upswing business wise but has suffered a beating by Mr. Market.

The growth rate has been steady over the past few years and most recently has been at a whopping 30% and change. The PE ratio is nearly half of that and as Peter Lynch would say, of course depending on the sector, that usually indicates a bargain.

ICLR has a ton of cash on hand and no major debts. There's been nothing but positive news about this company or for that matter the sector. I predict this will be back up to mid-$20's within the next two months for a short play and of course it would be a good buy now around or below $18 for the longer term of six to eights months.

Recs

0
Member Avatar tskephart (84.19) Submitted: 11/26/2008 12:45:58 PM : Outperform Start Price: $19.02 ICLR Score: +59.01

Will benefit from pharma outsourcing

Recs

0
Member Avatar elrap (82.09) Submitted: 10/28/2008 9:40:45 AM : Outperform Start Price: $24.25 ICLR Score: -2.39

In so far as it can be - this is a recession proof stock. CEO, Peter Gray was quoted as saying - "people don't stop buying medicines when there is a recession".

Recs

0
Member Avatar stockguy07 (< 20) Submitted: 8/13/2008 1:59:56 PM : Outperform Start Price: $41.65 ICLR Score: -25.94

TM - drug trial outsourcing

Recs

0
Member Avatar money4play (< 20) Submitted: 8/11/2008 3:32:22 PM : Outperform Start Price: $43.67 ICLR Score: -30.91

As big pharma trys to reduce costs of geting products to market they will rely more heavily on outsourcing clinical trials.

Recs

0
Member Avatar Option1307 (29.75) Submitted: 8/5/2008 1:43:27 AM : Outperform Start Price: $41.25 ICLR Score: -28.38

I agree with most that outsouring is going to continue to be an important aspect of the biotech/pharma cost-cutting methods. ICLR is based in Ireland which gives it some insulation against the slowing US economy; however, I doubt the economy will effect this industry either way.

Good balance sheet, increasing sales, EPS, cash flow last 3 yrs. RoE of 16% is mediocre but better than most competitors. P/S of 2.82. IBD rating of 90/96 for EPS/price strength respectively. 17% inside ownership is a nice addition as well.

I know I'm coming in high, but it looks as if its ready to run some more, its still got more Irish luck...

Results 1 - 20 of 38 : 1 2 Next »

Featured Broker Partners


Advertisement